P&G Actonel Payment Postponed: $50 Mil. Delay Contributes To $40 Bil. Drop
Executive Summary
The delay in the approval of Procter & Gamble's Actonel for osteoporosis contributed to the company's $38.7 bil. drop in value following the March 7 announcement that it will miss its earnings targets.
You may also be interested in...
P&G Taps Lafley To Turn "Tide" In Earnings: Pepper Returns As Chairman
Procter & Gamble CEO-elect A.G. Lafley will inherit the task of settling the appropriate size for P&G's investment in the pharmaceutical business.
P&G Taps Lafley To Turn "Tide" In Earnings: Pepper Returns As Chairman
Procter & Gamble CEO-elect A.G. Lafley will inherit the task of settling the appropriate size for P&G's investment in the pharmaceutical business.
AHP Redux Liability May Provide Two-Month Respite From Merger Offers
American Home Products may have until the end of March to weigh its options before facing the prospect of hostile takeover offers.